<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00096720</url>
  </required_header>
  <id_info>
    <org_study_id>INSPECT</org_study_id>
    <nct_id>NCT00096720</nct_id>
  </id_info>
  <brief_title>Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease</brief_title>
  <official_title>Investigating Effects of Short-term Treatment With Pramipexole or Levodopa on [123I]B-CIT and SPECT Imaging in Early Parkinson's</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute for Neurodegenerative Disorders</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute for Neurodegenerative Disorders</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study participants who have been clinically diagnosed with Parkinson disease will receive no
      treatment, treatment with either levodopa, or treatment with Mirapex for a period of 12
      weeks. Over the course of the study subjects will travel to the Institute for
      Neurodegenerative Disorders (IND) in New Haven, Connecticut for brain imaging.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Brain imaging will be conducted three times during this study. Study participants will travel
      to IND for [123I]ß-CIT and SPECT imaging (scan 1). Subjects will be randomized to no
      treatment, treatment with either levodopa, or treatment with Mirapex and undergo treatment
      for a period of 12 weeks. Subjects will return to IND for [123I]ß-CIT and SPECT imaging (scan
      2) after 12 weeks of treatment and withdraw from the medication following the scan. Eight to
      12 weeks after medication withdrawal, a final [123I]ß-CIT and SPECT imaging study (scan 3)
      will be performed at IND. The imaging outcome, striatal uptake of [123I]ß-CIT, from scan 1
      (untreated) and scan 2 (treated with levodopa or pramipexole) will be compared to determine
      if there is a significant change in the uptake of the marker that may be attributed to
      levodopa or pramipexole treatment. In addition, scan 3 will be compared to scan 2 to
      determine the duration and reversibility of any regulatory effect that occurs. The subjects
      will be randomized, but not blinded to study drug assignment. The imaging technologist and
      all imaging analyses will be performed by investigators blinded to study drug assignment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in outcomes from scan 1 to scan 2</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in outcomes from scan 2 to scan 3</measure>
  </secondary_outcome>
  <enrollment type="Actual">112</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>Parkinsonian Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levodopa</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirapex (pramipexole)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>[123I]ß-CIT and SPECT imaging</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  30 years or older at time of Parkinson Disease (PD) diagnosis

          -  clinical diagnosis of PD of equal to or less than 7.5 years

          -  Normal laboratory screening

        Exclusion Criteria:

          -  Participant is pregnant

          -  Participant has atypical or drug induced PD

          -  Participant has significant dementia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Danna Jennings, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Neurodegenerative Disorders</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pacific Neuroscience Medical Group</name>
      <address>
        <city>Oxnard</city>
        <state>California</state>
        <zip>93030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Neurology, PC</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Neurodegenerative Disorders</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Movement Disorders Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RUSH University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lahey Clinic Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkinson's Disease and Movement Disorders Center of Albany Medical College</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NeuroHealth, Inc.</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Health Science Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38163</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ahlskog JE. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology. 2003 Feb 11;60(3):381-9. Review.</citation>
    <PMID>12580184</PMID>
  </reference>
  <reference>
    <citation>Ahlskog JE, Uitti RJ, O'Connor MK, Maraganore DM, Matsumoto JY, Stark KF, Turk MF, Burnett OL. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease. Mov Disord. 1999 Nov;14(6):940-6.</citation>
    <PMID>10584667</PMID>
  </reference>
  <reference>
    <citation>Brücke T, Asenbaum S, Pirker W, Djamshidian S, Wenger S, Wöber C, Müller C, Podreka I. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl. 1997;50:9-24.</citation>
    <PMID>9120429</PMID>
  </reference>
  <reference>
    <citation>Fahn S. Is levodopa toxic? Neurology. 1996 Dec;47(6 Suppl 3):S184-95. Review.</citation>
    <PMID>8959987</PMID>
  </reference>
  <reference>
    <citation>Guttman M, Stewart D, Hussey D, Wilson A, Houle S, Kish S. Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD. Neurology. 2001 Jun 12;56(11):1559-64.</citation>
    <PMID>11402115</PMID>
  </reference>
  <reference>
    <citation>Innis RB, Seibyl JP, Scanley BE, Laruelle M, Abi-Dargham A, Wallace E, Baldwin RM, Zea-Ponce Y, Zoghbi S, Wang S, et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11965-9.</citation>
    <PMID>8265656</PMID>
  </reference>
  <reference>
    <citation>Innis RB, Marek KL, Sheff K, Zoghbi S, Castronuovo J, Feigin A, Seibyl JP. Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT. Mov Disord. 1999 May;14(3):436-42.</citation>
    <PMID>10348466</PMID>
  </reference>
  <reference>
    <citation>Little KY, Gorebig J, Carroll FI, Mapili J, Meador-Woodruff JH. Lack of dopamine receptor agonists effect on striatal dopamine transporter binding sites. Brain Res. 1996 Dec 2;742(1-2):313-6.</citation>
    <PMID>9117410</PMID>
  </reference>
  <reference>
    <citation>Marek K, Innis R, van Dyck C, Fussell B, Early M, Eberly S, Oakes D, Seibyl J. [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology. 2001 Dec 11;57(11):2089-94.</citation>
    <PMID>11739831</PMID>
  </reference>
  <reference>
    <citation>Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry. 1998 Mar;64(3):314-9.</citation>
    <PMID>9527140</PMID>
  </reference>
  <reference>
    <citation>Nurmi E, Bergman J, Eskola O, Solin O, Hinkka SM, Sonninen P, Rinne JO. Reproducibility and effect of levodopa on dopamine transporter function measurements: a [18F]CFT PET study. J Cereb Blood Flow Metab. 2000 Nov;20(11):1604-9.</citation>
    <PMID>11083235</PMID>
  </reference>
  <reference>
    <citation>Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA. 2002 Apr 3;287(13):1653-61.</citation>
    <PMID>11926889</PMID>
  </reference>
  <reference>
    <citation>Fahn S; Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol. 2005 Oct;252 Suppl 4:IV37-IV42. Review.</citation>
    <PMID>16222436</PMID>
  </reference>
  <reference>
    <citation>Rioux L, Frohna PA, Joyce JN, Schneider JS. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys. Mov Disord. 1997 Mar;12(2):148-58.</citation>
    <PMID>9087972</PMID>
  </reference>
  <reference>
    <citation>Schapira AH. Dopamine agonists and neuroprotection in Parkinson's disease. Eur J Neurol. 2002 Nov;9 Suppl 3:7-14. Review.</citation>
    <PMID>12464116</PMID>
  </reference>
  <reference>
    <citation>Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, Poewe WH, Hauser RA, Brooks DJ; REAL-PET Study Group. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol. 2003 Jul;54(1):93-101.</citation>
    <PMID>12838524</PMID>
  </reference>
  <reference>
    <citation>Wooten GF. Agonists vs levodopa in PD: the thrilla of whitha. Neurology. 2003 Feb 11;60(3):360-2.</citation>
    <PMID>12578913</PMID>
  </reference>
  <verification_date>May 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2004</study_first_submitted>
  <study_first_submitted_qc>November 12, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2004</study_first_posted>
  <last_update_submitted>September 28, 2010</last_update_submitted>
  <last_update_submitted_qc>September 28, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2010</last_update_posted>
  <responsible_party>
    <name_title>Danna Jennings M.D.</name_title>
    <organization>Institute for Neurodegenerative Disorders</organization>
  </responsible_party>
  <keyword>parkinson</keyword>
  <keyword>brain imaging</keyword>
  <keyword>diagnosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Pramipexole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

